Our Team – PRECLINICAL SCIENCE

Preclinical Science

PRECLINICAL SCIENCE was founded in 2016 by Dr. Roman Föll and Dr. Lars Mecklenburg. It is registered in Münster, Germany, as Föll, Mecklenburg & Partner GmbH. Both founders and newly joined partner Dr. Geertje Lewin bring 30 years of experience in research and development into the business. We have a different focus, though, and supplement our experience with the expertise of partners with whom we maintain a very close working relationship. Our philosophy is a true partnership with our clients and an honest consultation at the highest scientific standard.

Laura-Katharina Bertels

Laura-Katharina Bertels finished her master degree in cellular and molecular biology at the University of Osnabrück in 2019 after obtaining a B.Sc. in Biotechnology from Hochschule Furtwangen University, Germany. Since 2016 she worked as a medical writer in preclinical drug development at Dr. Roman Föll Preclinical Services.

After the founding of Preclinical Science Föll, Mecklenburg & Partner GmbH she continued working for the company.

General Manager

Dr. Roman Föll studied biology/zoology at the Ludwig-Maximilians-University in Munich, Germany. He made his PhD in biophysics and physiology. Dr. Föll was an assistant professor in zoo physiology at the Westfalian Wilhelms-University in Münster, Germany, and a scientist in inhalation toxicology at Boehringer Ingelheim Pharma KG.

Later on, he became senior researcher and study director at ALTANA Pharma AG, where he supervised rodent toxicology and immunotoxicology. Since 2006, Dr. Föll works as an independent consultant in preclinical development for drugs and chemicals. He is a European Registered Toxicologist (ERT) since 2008, and has given lectures on toxicology in various academic programs throughout Germany.

Dr. Erinita Fröhlke

Dr. Erinita Fröhlke studied biology in Berlin, Aachen, Cologne and Heidelberg, Germany, obtained her diploma degree at the German Cancer Institute, Heidelberg and her PhD at the Westfalian Wilhelms-University in Muenster, Germany. She served for 20 years as quality control manager at various CROs and pharmaceutical companies.

Since 2014, Dr. Fröhlke works as a consultant and auditor for GLP (preclinical studies) and animal welfare issues. The services encompass audits on study performance, raw data and documents, quality system and SOPs, vendors/suppliers and for qualification. The experience in animal welfare issues includes qualification as Animal Welfare Officer, member of the IACUC (Institutional Animal Care and Use Committee). Dr. Fröhlke is an experienced trainer of courses in animal welfare laws according to German and international regulations.

Dr. Silvia Guionaud

Dr. Silvia Guionaud received her degree in veterinary sciences and PhD in veterinary pathology from Hannover Veterinary School in Germany. She became a Diplomate of the European College of Veterinary Pathology (ECVP) in 2006.
Dr. Guionaud has a strong background in both investigative and regulatory toxicological pathology and has worked for both small and large biopharmaceutical companies.

Past positions include therapeutic area lead for early safety strategy at Pfizer, head of projects for safety assessment at Millennium, director of pathology at Millennium and Shire, and global head of pathology at AstraZeneca. She has a scientific interest in vascular injury, safety biomarker development, and immuneooncology.
Since April 2019, Dr. Guionaud has been working as independent consultant. She is author to numerous scientific publications in the field of toxicological pathology and biomarker development.

Madeleine Joel

Madeleine Joel studied molecular biotechnology (B.Sc.) at the Ruprecht-Karls-University of Heidelberg, Germany and made her bachelor thesis in the field of melanoma immunotherapy at the German Cancer Research Center, Heidelberg, Germany. Afterwards, she studied toxicology (M.Sc.) at the Technical University of Kaiserslautern, Germany and performed her master’s degree in genotoxicology/stem cell research at King’s College London, Great Britain, where she worked afterwards as research assistant.

Before studying, she worked as medical laboratory assistant in the fields of clinical chemistry/biochemistry, hematology, coagulation, blood typing/depot, immunology, infection serology, radioimmunoassay and microbiology in several institutes of laboratory medicine, Germany. Madeleine Joel joined our company in 2017. Since 2018, she performs further training in toxicology to become a European Registered Toxicologist (ERT).

Prof. Robert Klopfleisch

Robert Klopfleisch studied veterinary medicine at the University of Leipzig and obtained his PhD at the Friedrich-Loeffler-Institute and University Giessen. Robert Klopfleisch is a pathologist, certified by the American College of Veterinary Pathologists. He has extensive experience in the pathology evaluation of preclinical studies and has authored more than 170 publications.

Robert Klopfleisch works as an assistant professor for veterinary pathology at the Free University of Berlin and is an external consultant to Föll, Mecklenburg & Partner, where he evaluates slides from GLP and non-GLP toxicity studies and provides pathology expert reports.

General Manager

Dr. Geertje Lewin studied ecology and biology in Cambridge, US and Greifswald, Germany and obtained her PhD in zoophysiology. She worked as researcher and lecturer in pharmacology and toxicology at the Westfalian Wilhelms-University in Muenster, Germany. As a study director in reproductive toxicology and risk assessor for chemicals, Dr. Lewin worked at the Fraunhofer Institute for Toxicology and Experimental Medicine, Germany in GLP studies, developed alternative testing methods and new in-vivo/in vitro models.

Dr. Lewin was council member of the European Teratology Society, works as an independent consultant since 2014, is a European Registered Toxicologist (ERT) via the UK register for Toxicologists since 2016 and Member of the Royal Society of Biologists (MRSB) since 2018. She has published numerous articles on cardiac pharmacology, alternative methods in risk assessment and reproductive toxicology (pre- and postnatal development, juvenile toxicity in drug development).

Co-Founder, currently not contributing to consulting

Dr. Lars Mecklenburg studied veterinary medicine at the Veterinary School in Hannover, Germany. He achieved his PhD in pathology and is certified as a pathologist in Germany. In 2009, Dr. Mecklenburg became a Diplomate of the American College of Veterinary Pathologists (ACVP) and in 2012, he was certified as an Advanced Risk Assessor by the European TRISK program.

Dr. Mecklenburg worked as a toxicologic pathologist at ALTANA Pharma AG, headed preclinical program management at Nycomed GmbH, was Vice President for the Biorepository at Indivumed GmbH, and Vice President for Global Preclinical Development at Fresenius Kabi Deutschland. He worked as a consultant 2014-19, and has published numerous scientific articles in the fields of pathology, experimental dermatology, and preclinical drug development.

Ulrich Schreiber

Ulrich Schreiber studied Chemistry at the Westfalian Wilhelms-University in Muenster, Germany. He finished his Bachelor´s thesis in 2015 in the field of organic synthesis. Afterwards he obtained his MSc in Toxicology at the Charité in Berlin and finished his Master´s thesis in method development for detection of cannabinoids in serum in 2017. Before starting to work as a toxicologist for Preclinical Science in 2019 he worked as a Research Assistant at the Interdisciplinary Center for Clinical Research at the University Hospital in Münster.